Three-year follow-up of a novel aqueous humor microshunt

Juan F. Batlle, Francisco Fantes, Isabelle Riss, Leonard Pinchuk, Rachel Alburquerque, Yasushi P. Kato, Esdras Arrieta Quintero, Adalgisa Corona Peralta, Paul Palmberg, Richard K Parrish, Bruce A. Weber, Jean-Marie A Parel

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Aims: An observational study to determine the safety and efficacy of filtering surgery employing a microlumen aqueous drainage device (InnFocus MicroShunt), used intraoperatively with Mitomycin C, implanted alone or in combination with phacoemulsification. Materials and Methods: Single-site, prospective, nonrandomized study of 23 eyes that had failed maximum tolerated glaucoma medication, followed for 3 years. A MicroShunt was implanted ab externo through a needle tract under the limbus, draining aqueous from the anterior chamber to the scleral surface. Prespecified outcome measures include: intraocular pressure (IOP) control, with and without supplemental medication, success rate, medication use, and adverse events. Results: Fourteen patients received the MicroShunt alone and 9 with cataract surgery. At 1 (n=23), 2 (n=22), and 3 (n=22) years of follow-up; the qualified success rate (IOP≤14mm Hg and IOP reduction ≥20%) was 100%, 91%, and 95%; mean medicated IOP was reduced from 23.8±5.3 to 10.7±2.8, 11.9±3.7, and 10.7±3.5mm Hg, and the mean number of glaucoma medications/ patient was reduced from 2.4±0.9 to 0.3±0.8, 0.4±1.0, and 0.7±1.1, respectively. The most common complications were transient hypotony (13%, 3/23) and transient choroidal effusion (8.7%, 2/23), all resolved spontaneously. There were no leaks, infections, migrations, erosions, persistent corneal edema, or serious long-term adverse events. Conclusion: Surgery with the InnFocus MicroShunt transscleral aqueous drainage tube with Mitomycin C achieved IOP control in the low teens in most subjects up to 3 years of follow-up with only transient adverse events occurring within the first 3 months after surgery.

Original languageEnglish (US)
Pages (from-to)e58-e65
JournalJournal of Glaucoma
Volume25
Issue number2
DOIs
StatePublished - Jan 28 2016

Fingerprint

Aqueous Humor
Intraocular Pressure
Mitomycin
Glaucoma
Drainage
Filtering Surgery
Corneal Edema
Phacoemulsification
Anterior Chamber
Cataract
Needles
Observational Studies
Outcome Assessment (Health Care)
Prospective Studies
Safety
Equipment and Supplies
Infection

Keywords

  • Aqueous humor
  • Glaucoma
  • Glaucoma drainage tube
  • Minimally invasive surgery
  • Shunt
  • Treatment surgery

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Batlle, J. F., Fantes, F., Riss, I., Pinchuk, L., Alburquerque, R., Kato, Y. P., ... Parel, J-M. A. (2016). Three-year follow-up of a novel aqueous humor microshunt. Journal of Glaucoma, 25(2), e58-e65. https://doi.org/10.1097/IJG.0000000000000368

Three-year follow-up of a novel aqueous humor microshunt. / Batlle, Juan F.; Fantes, Francisco; Riss, Isabelle; Pinchuk, Leonard; Alburquerque, Rachel; Kato, Yasushi P.; Arrieta Quintero, Esdras; Peralta, Adalgisa Corona; Palmberg, Paul; Parrish, Richard K; Weber, Bruce A.; Parel, Jean-Marie A.

In: Journal of Glaucoma, Vol. 25, No. 2, 28.01.2016, p. e58-e65.

Research output: Contribution to journalArticle

Batlle, JF, Fantes, F, Riss, I, Pinchuk, L, Alburquerque, R, Kato, YP, Arrieta Quintero, E, Peralta, AC, Palmberg, P, Parrish, RK, Weber, BA & Parel, J-MA 2016, 'Three-year follow-up of a novel aqueous humor microshunt', Journal of Glaucoma, vol. 25, no. 2, pp. e58-e65. https://doi.org/10.1097/IJG.0000000000000368
Batlle JF, Fantes F, Riss I, Pinchuk L, Alburquerque R, Kato YP et al. Three-year follow-up of a novel aqueous humor microshunt. Journal of Glaucoma. 2016 Jan 28;25(2):e58-e65. https://doi.org/10.1097/IJG.0000000000000368
Batlle, Juan F. ; Fantes, Francisco ; Riss, Isabelle ; Pinchuk, Leonard ; Alburquerque, Rachel ; Kato, Yasushi P. ; Arrieta Quintero, Esdras ; Peralta, Adalgisa Corona ; Palmberg, Paul ; Parrish, Richard K ; Weber, Bruce A. ; Parel, Jean-Marie A. / Three-year follow-up of a novel aqueous humor microshunt. In: Journal of Glaucoma. 2016 ; Vol. 25, No. 2. pp. e58-e65.
@article{34f22a41073b45f0823685d6e775aeb4,
title = "Three-year follow-up of a novel aqueous humor microshunt",
abstract = "Aims: An observational study to determine the safety and efficacy of filtering surgery employing a microlumen aqueous drainage device (InnFocus MicroShunt), used intraoperatively with Mitomycin C, implanted alone or in combination with phacoemulsification. Materials and Methods: Single-site, prospective, nonrandomized study of 23 eyes that had failed maximum tolerated glaucoma medication, followed for 3 years. A MicroShunt was implanted ab externo through a needle tract under the limbus, draining aqueous from the anterior chamber to the scleral surface. Prespecified outcome measures include: intraocular pressure (IOP) control, with and without supplemental medication, success rate, medication use, and adverse events. Results: Fourteen patients received the MicroShunt alone and 9 with cataract surgery. At 1 (n=23), 2 (n=22), and 3 (n=22) years of follow-up; the qualified success rate (IOP≤14mm Hg and IOP reduction ≥20{\%}) was 100{\%}, 91{\%}, and 95{\%}; mean medicated IOP was reduced from 23.8±5.3 to 10.7±2.8, 11.9±3.7, and 10.7±3.5mm Hg, and the mean number of glaucoma medications/ patient was reduced from 2.4±0.9 to 0.3±0.8, 0.4±1.0, and 0.7±1.1, respectively. The most common complications were transient hypotony (13{\%}, 3/23) and transient choroidal effusion (8.7{\%}, 2/23), all resolved spontaneously. There were no leaks, infections, migrations, erosions, persistent corneal edema, or serious long-term adverse events. Conclusion: Surgery with the InnFocus MicroShunt transscleral aqueous drainage tube with Mitomycin C achieved IOP control in the low teens in most subjects up to 3 years of follow-up with only transient adverse events occurring within the first 3 months after surgery.",
keywords = "Aqueous humor, Glaucoma, Glaucoma drainage tube, Minimally invasive surgery, Shunt, Treatment surgery",
author = "Batlle, {Juan F.} and Francisco Fantes and Isabelle Riss and Leonard Pinchuk and Rachel Alburquerque and Kato, {Yasushi P.} and {Arrieta Quintero}, Esdras and Peralta, {Adalgisa Corona} and Paul Palmberg and Parrish, {Richard K} and Weber, {Bruce A.} and Parel, {Jean-Marie A}",
year = "2016",
month = "1",
day = "28",
doi = "10.1097/IJG.0000000000000368",
language = "English (US)",
volume = "25",
pages = "e58--e65",
journal = "Journal of Glaucoma",
issn = "1057-0829",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Three-year follow-up of a novel aqueous humor microshunt

AU - Batlle, Juan F.

AU - Fantes, Francisco

AU - Riss, Isabelle

AU - Pinchuk, Leonard

AU - Alburquerque, Rachel

AU - Kato, Yasushi P.

AU - Arrieta Quintero, Esdras

AU - Peralta, Adalgisa Corona

AU - Palmberg, Paul

AU - Parrish, Richard K

AU - Weber, Bruce A.

AU - Parel, Jean-Marie A

PY - 2016/1/28

Y1 - 2016/1/28

N2 - Aims: An observational study to determine the safety and efficacy of filtering surgery employing a microlumen aqueous drainage device (InnFocus MicroShunt), used intraoperatively with Mitomycin C, implanted alone or in combination with phacoemulsification. Materials and Methods: Single-site, prospective, nonrandomized study of 23 eyes that had failed maximum tolerated glaucoma medication, followed for 3 years. A MicroShunt was implanted ab externo through a needle tract under the limbus, draining aqueous from the anterior chamber to the scleral surface. Prespecified outcome measures include: intraocular pressure (IOP) control, with and without supplemental medication, success rate, medication use, and adverse events. Results: Fourteen patients received the MicroShunt alone and 9 with cataract surgery. At 1 (n=23), 2 (n=22), and 3 (n=22) years of follow-up; the qualified success rate (IOP≤14mm Hg and IOP reduction ≥20%) was 100%, 91%, and 95%; mean medicated IOP was reduced from 23.8±5.3 to 10.7±2.8, 11.9±3.7, and 10.7±3.5mm Hg, and the mean number of glaucoma medications/ patient was reduced from 2.4±0.9 to 0.3±0.8, 0.4±1.0, and 0.7±1.1, respectively. The most common complications were transient hypotony (13%, 3/23) and transient choroidal effusion (8.7%, 2/23), all resolved spontaneously. There were no leaks, infections, migrations, erosions, persistent corneal edema, or serious long-term adverse events. Conclusion: Surgery with the InnFocus MicroShunt transscleral aqueous drainage tube with Mitomycin C achieved IOP control in the low teens in most subjects up to 3 years of follow-up with only transient adverse events occurring within the first 3 months after surgery.

AB - Aims: An observational study to determine the safety and efficacy of filtering surgery employing a microlumen aqueous drainage device (InnFocus MicroShunt), used intraoperatively with Mitomycin C, implanted alone or in combination with phacoemulsification. Materials and Methods: Single-site, prospective, nonrandomized study of 23 eyes that had failed maximum tolerated glaucoma medication, followed for 3 years. A MicroShunt was implanted ab externo through a needle tract under the limbus, draining aqueous from the anterior chamber to the scleral surface. Prespecified outcome measures include: intraocular pressure (IOP) control, with and without supplemental medication, success rate, medication use, and adverse events. Results: Fourteen patients received the MicroShunt alone and 9 with cataract surgery. At 1 (n=23), 2 (n=22), and 3 (n=22) years of follow-up; the qualified success rate (IOP≤14mm Hg and IOP reduction ≥20%) was 100%, 91%, and 95%; mean medicated IOP was reduced from 23.8±5.3 to 10.7±2.8, 11.9±3.7, and 10.7±3.5mm Hg, and the mean number of glaucoma medications/ patient was reduced from 2.4±0.9 to 0.3±0.8, 0.4±1.0, and 0.7±1.1, respectively. The most common complications were transient hypotony (13%, 3/23) and transient choroidal effusion (8.7%, 2/23), all resolved spontaneously. There were no leaks, infections, migrations, erosions, persistent corneal edema, or serious long-term adverse events. Conclusion: Surgery with the InnFocus MicroShunt transscleral aqueous drainage tube with Mitomycin C achieved IOP control in the low teens in most subjects up to 3 years of follow-up with only transient adverse events occurring within the first 3 months after surgery.

KW - Aqueous humor

KW - Glaucoma

KW - Glaucoma drainage tube

KW - Minimally invasive surgery

KW - Shunt

KW - Treatment surgery

UR - http://www.scopus.com/inward/record.url?scp=84957433673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957433673&partnerID=8YFLogxK

U2 - 10.1097/IJG.0000000000000368

DO - 10.1097/IJG.0000000000000368

M3 - Article

C2 - 26766400

AN - SCOPUS:84957433673

VL - 25

SP - e58-e65

JO - Journal of Glaucoma

JF - Journal of Glaucoma

SN - 1057-0829

IS - 2

ER -